CN114667148A - 用jak抑制剂治疗汗腺炎 - Google Patents
用jak抑制剂治疗汗腺炎 Download PDFInfo
- Publication number
- CN114667148A CN114667148A CN202080078318.5A CN202080078318A CN114667148A CN 114667148 A CN114667148 A CN 114667148A CN 202080078318 A CN202080078318 A CN 202080078318A CN 114667148 A CN114667148 A CN 114667148A
- Authority
- CN
- China
- Prior art keywords
- methyl
- pyrimidin
- amino
- pyrazol
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002557 hidradenitis Diseases 0.000 title claims abstract description 64
- 238000011282 treatment Methods 0.000 title claims description 23
- 229940122245 Janus kinase inhibitor Drugs 0.000 title claims description 6
- 238000000034 method Methods 0.000 claims abstract description 74
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims abstract description 60
- 230000003902 lesion Effects 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 28
- 230000037396 body weight Effects 0.000 claims description 26
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims description 15
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims description 15
- 206010000269 abscess Diseases 0.000 claims description 14
- 230000002757 inflammatory effect Effects 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 12
- XPLZTJWZDBFWDE-UHFFFAOYSA-N 3-(cyanomethyl)-3-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]cyclobutane-1-carbonitrile Chemical group CN1C=C(C=N1)C1=CN2N=CC=C2C(=N1)C1=CN(N=C1)C1(CC#N)CC(C1)C#N XPLZTJWZDBFWDE-UHFFFAOYSA-N 0.000 claims description 11
- 206010016717 Fistula Diseases 0.000 claims description 9
- 230000003890 fistula Effects 0.000 claims description 9
- IUEWXNHSKRWHDY-UHFFFAOYSA-N N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide Chemical group C1C(NS(=O)(=O)CCC)CC1N(C)C1=NC=NC2=C1C=CN2 IUEWXNHSKRWHDY-UHFFFAOYSA-N 0.000 claims description 8
- BUWBRTXGQRBBHG-MJBXVCDLSA-N FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F Chemical group FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F BUWBRTXGQRBBHG-MJBXVCDLSA-N 0.000 claims description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical group CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- BUWBRTXGQRBBHG-HZSPNIEDSA-N FC1([C@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F Chemical group FC1([C@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F BUWBRTXGQRBBHG-HZSPNIEDSA-N 0.000 claims description 2
- 229940123371 Tyrosine kinase 2 inhibitor Drugs 0.000 claims 4
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 abstract description 33
- 108010024121 Janus Kinases Proteins 0.000 abstract description 4
- 102000015617 Janus Kinases Human genes 0.000 abstract description 4
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 4
- 102000020233 phosphotransferase Human genes 0.000 abstract description 4
- -1 5- ({4- [ (1R,5S) -8- { [ (1R,2S) -2-fluorocyclopropyl ] carbonyl } -3, 8-diazabicyclo [3.2.1] oct-3-yl ] pyrimidin-2-yl } amino) -N, 3-dimethylpyrimidine-2-carboxamide Chemical compound 0.000 description 40
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 25
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 239000003112 inhibitor Substances 0.000 description 16
- 201000010099 disease Diseases 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 229960002964 adalimumab Drugs 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000042838 JAK family Human genes 0.000 description 5
- 108091082332 JAK family Proteins 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229940044551 receptor antagonist Drugs 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 231100000241 scar Toxicity 0.000 description 5
- 208000032544 Cicatrix Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 4
- 210000001099 axilla Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229960002052 salbutamol Drugs 0.000 description 4
- 230000037390 scarring Effects 0.000 description 4
- 230000037387 scars Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000038030 PI3Ks Human genes 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 210000004013 groin Anatomy 0.000 description 3
- 210000001624 hip Anatomy 0.000 description 3
- 230000001969 hypertrophic effect Effects 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 2
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- NNXCVXSDVVSEDL-VHRNVKJDSA-N CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(CC#N)C Chemical compound CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(CC#N)C NNXCVXSDVVSEDL-VHRNVKJDSA-N 0.000 description 2
- ZEIXJLFZPBDRBT-SRABZTEZSA-N CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C[C@@H]1[C@H](C1)C#N Chemical compound CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C[C@@H]1[C@H](C1)C#N ZEIXJLFZPBDRBT-SRABZTEZSA-N 0.000 description 2
- 102100029391 Cardiotrophin-like cytokine factor 1 Human genes 0.000 description 2
- 101710107109 Cardiotrophin-like cytokine factor 1 Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VGQRFGDVWYLOHZ-LJISPDSOSA-N F[C@H]1[C@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C Chemical compound F[C@H]1[C@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C VGQRFGDVWYLOHZ-LJISPDSOSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 description 2
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940092705 beclomethasone Drugs 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- 229940124748 beta 2 agonist Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 2
- 229960003088 loratadine Drugs 0.000 description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 239000003681 muscarinic M3 receptor antagonist Substances 0.000 description 2
- 229940127249 oral antibiotic Drugs 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000002640 perineum Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- OVBICQMTCPFEBS-SATRDZAXSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound CC(O)=O.CC(O)=O.C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 OVBICQMTCPFEBS-SATRDZAXSA-N 0.000 description 1
- PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 1
- ZEJGQLBINOBMRS-UHFFFAOYSA-N 2-[1-(cyanomethyl)-3-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CN1N=CC(=C1)C=1N=C(C=2N(C=1)N=CC=2)C=1C=NN(C=1)C1(CN(C1)CC#N)CC#N ZEJGQLBINOBMRS-UHFFFAOYSA-N 0.000 description 1
- GUKVYGJJKLTNBV-UHFFFAOYSA-N 2-[1-[4-[6-(3-amino-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]-3-methoxycyclobutyl]acetonitrile Chemical compound COC1CC(CC#N)(C1)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=CC(N)=NN1 GUKVYGJJKLTNBV-UHFFFAOYSA-N 0.000 description 1
- DEAIYWLINRLCNK-UHFFFAOYSA-N 2-[1-[4-[6-[5-(hydroxymethyl)-1H-pyrazol-3-yl]pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]-3-methoxycyclobutyl]acetonitrile Chemical compound COC1CC(CC#N)(C1)N1C=C(C=N1)C1=NC(=CN2N=CC=C12)C1=NNC(CO)=C1 DEAIYWLINRLCNK-UHFFFAOYSA-N 0.000 description 1
- XNFKXDZAZBECJS-UHFFFAOYSA-N 2-[1-ethyl-3-[4-[6-[5-(hydroxymethyl)-1H-pyrazol-3-yl]pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C(C)N1CC(C1)(N1N=CC(=C1)C=1C=2N(C=C(N=1)C1=NNC(=C1)CO)N=CC=2)CC#N XNFKXDZAZBECJS-UHFFFAOYSA-N 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- CVJGOZKZLJNGAE-UHFFFAOYSA-N 3-(cyanomethyl)-3-[4-[3-methyl-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]cyclobutane-1-carbonitrile Chemical compound CN1C=C(C=N1)C1=CN2N=CC(C)=C2C(=N1)C1=CN(N=C1)C1(CC#N)CC(C1)C#N CVJGOZKZLJNGAE-UHFFFAOYSA-N 0.000 description 1
- AMCWIARZLJUBEG-UHFFFAOYSA-N 3-(cyanomethyl)-3-[4-[6-(2-methyl-5-oxo-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]cyclobutane-1-carbonitrile Chemical compound CN1NC(=O)C(=C1)C1=CN2N=CC=C2C(=N1)C1=CN(N=C1)C1(CC#N)CC(C1)C#N AMCWIARZLJUBEG-UHFFFAOYSA-N 0.000 description 1
- HKTJARAZYORKAF-UHFFFAOYSA-N 3-[4-[6-(3-amino-1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]-3-(cyanomethyl)cyclobutane-1-carbonitrile Chemical compound CN1C=C(C(N)=N1)C1=CN2N=CC=C2C(=N1)C1=CN(N=C1)C1(CC#N)CC(C1)C#N HKTJARAZYORKAF-UHFFFAOYSA-N 0.000 description 1
- 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 description 1
- 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- GJCRLBVUCZFFSC-UHFFFAOYSA-N C(#N)CC(=O)N1C2CN(CC1CC2)C1=NC(=NC=C1)NC1=CC=C(C(=O)NCC)C=C1 Chemical compound C(#N)CC(=O)N1C2CN(CC1CC2)C1=NC(=NC=C1)NC1=CC=C(C(=O)NCC)C=C1 GJCRLBVUCZFFSC-UHFFFAOYSA-N 0.000 description 1
- UDLSXJQTHFRFDT-GASCZTMLSA-N C(#N)CCNC(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C Chemical compound C(#N)CCNC(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C UDLSXJQTHFRFDT-GASCZTMLSA-N 0.000 description 1
- RDBPTNPTWAHSBQ-OKILXGFUSA-N C(#N)CNC(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C Chemical compound C(#N)CNC(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C RDBPTNPTWAHSBQ-OKILXGFUSA-N 0.000 description 1
- XALRWMAIPZZSON-AQEPXONASA-N C(#N)[C@@H]1C[C@H](C1)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=C(C(=NC=1)C(=O)NC)C Chemical compound C(#N)[C@@H]1C[C@H](C1)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=C(C(=NC=1)C(=O)NC)C XALRWMAIPZZSON-AQEPXONASA-N 0.000 description 1
- XALRWMAIPZZSON-JEGGMEIXSA-N C(#N)[C@H]1C[C@H](C1)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=C(C(=NC=1)C(=O)NC)C Chemical compound C(#N)[C@H]1C[C@H](C1)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=C(C(=NC=1)C(=O)NC)C XALRWMAIPZZSON-JEGGMEIXSA-N 0.000 description 1
- FVXQLOUYMAEKMF-OKILXGFUSA-N C(C)NC(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NC(=C(C=1)F)C(NC)=O Chemical compound C(C)NC(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NC(=C(C=1)F)C(NC)=O FVXQLOUYMAEKMF-OKILXGFUSA-N 0.000 description 1
- RSTDYANUDZASGW-BETUJISGSA-N C(C)NC(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NNC=1 Chemical compound C(C)NC(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NNC=1 RSTDYANUDZASGW-BETUJISGSA-N 0.000 description 1
- SDCIUEURTOJUFC-BETUJISGSA-N C(C)NC(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NSC=1 Chemical compound C(C)NC(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NSC=1 SDCIUEURTOJUFC-BETUJISGSA-N 0.000 description 1
- ISQGUVXYSCPBBI-OKILXGFUSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)C1=CC(C#N)=CC=N1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)C1=CC(C#N)=CC=N1 ISQGUVXYSCPBBI-OKILXGFUSA-N 0.000 description 1
- AHTMSATVFMHGNS-BETUJISGSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)N1CCC(O)(C(F)(F)F)CC1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)N1CCC(O)(C(F)(F)F)CC1 AHTMSATVFMHGNS-BETUJISGSA-N 0.000 description 1
- WVPXLLNKSSQYKI-MELADBBJSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)N1CC[C@@H](C#N)C1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)N1CC[C@@H](C#N)C1 WVPXLLNKSSQYKI-MELADBBJSA-N 0.000 description 1
- WVPXLLNKSSQYKI-MCIONIFRSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)N1CC[C@H](C#N)C1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)N1CC[C@H](C#N)C1 WVPXLLNKSSQYKI-MCIONIFRSA-N 0.000 description 1
- HRRLZKHIEGDCQZ-APIJFGDWSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)[C@@H]1CC[C@@H](C#N)C1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)[C@@H]1CC[C@@H](C#N)C1 HRRLZKHIEGDCQZ-APIJFGDWSA-N 0.000 description 1
- HRRLZKHIEGDCQZ-XQLPTFJDSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)[C@H]1CC[C@H](C#N)C1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)[C@H]1CC[C@H](C#N)C1 HRRLZKHIEGDCQZ-XQLPTFJDSA-N 0.000 description 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- CWSVAVIMQYPSFF-IYBDPMFKSA-N C1(CC1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=C(C(=NC=1)C(=O)N)C Chemical compound C1(CC1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=C(C(=NC=1)C(=O)N)C CWSVAVIMQYPSFF-IYBDPMFKSA-N 0.000 description 1
- LUUOFVWWSXLXCD-HDICACEKSA-N C1(CC1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=C(C(=NC=1)C(=O)NCC)C Chemical compound C1(CC1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=C(C(=NC=1)C(=O)NCC)C LUUOFVWWSXLXCD-HDICACEKSA-N 0.000 description 1
- NFDUKDPMYWCESJ-GASCZTMLSA-N C1(CC1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C Chemical compound C1(CC1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C NFDUKDPMYWCESJ-GASCZTMLSA-N 0.000 description 1
- BGSBLEACDOXVBT-IYBDPMFKSA-N C1(CC1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)CCO Chemical compound C1(CC1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)CCO BGSBLEACDOXVBT-IYBDPMFKSA-N 0.000 description 1
- WYIJQOWAMUZNPW-OKILXGFUSA-N C1(CC1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NSC=1 Chemical compound C1(CC1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NSC=1 WYIJQOWAMUZNPW-OKILXGFUSA-N 0.000 description 1
- IVGALBBQTUXXJL-OKILXGFUSA-N C1(CC1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1F)NC1=CN=NC=C1 Chemical compound C1(CC1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1F)NC1=CN=NC=C1 IVGALBBQTUXXJL-OKILXGFUSA-N 0.000 description 1
- LAPJRNLLQCOCFQ-OKILXGFUSA-N C1(CC1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1F)NC1=NNC(=C1)C(=O)NCCC Chemical compound C1(CC1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1F)NC1=NNC(=C1)C(=O)NCCC LAPJRNLLQCOCFQ-OKILXGFUSA-N 0.000 description 1
- ZIVIAGNSDGIEPS-PVSQZPHNSA-N C1(CC1)C(=O)N[C@@]12CN(C[C@H]2[C@H]1C)C1=NC(=NC=C1F)NC=1C=C(C(=NC=1)C(=O)NC)C Chemical compound C1(CC1)C(=O)N[C@@]12CN(C[C@H]2[C@H]1C)C1=NC(=NC=C1F)NC=1C=C(C(=NC=1)C(=O)NC)C ZIVIAGNSDGIEPS-PVSQZPHNSA-N 0.000 description 1
- ZIVIAGNSDGIEPS-ZNVLZIIHSA-N C1(CC1)C(=O)N[C@]12CN(C[C@@H]2[C@@H]1C)C1=NC(=NC=C1F)NC=1C=C(C(=NC=1)C(=O)NC)C Chemical compound C1(CC1)C(=O)N[C@]12CN(C[C@@H]2[C@@H]1C)C1=NC(=NC=C1F)NC=1C=C(C(=NC=1)C(=O)NC)C ZIVIAGNSDGIEPS-ZNVLZIIHSA-N 0.000 description 1
- JXXOAWDMPAWACX-HAQNSBGRSA-N C1[C@@H](CS(=O)(=O)CCC)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 Chemical compound C1[C@@H](CS(=O)(=O)CCC)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 JXXOAWDMPAWACX-HAQNSBGRSA-N 0.000 description 1
- ZXVVBFKTMAKEGN-TXEJJXNPSA-N CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)N Chemical compound CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)N ZXVVBFKTMAKEGN-TXEJJXNPSA-N 0.000 description 1
- CLRRDVPHOPGUPT-GASCZTMLSA-N CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)NC(C)C Chemical compound CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)NC(C)C CLRRDVPHOPGUPT-GASCZTMLSA-N 0.000 description 1
- NJZRKNAKJSUCKN-IYBDPMFKSA-N CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)NC1=NC=C(C=C1)C(F)(F)F Chemical compound CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)NC1=NC=C(C=C1)C(F)(F)F NJZRKNAKJSUCKN-IYBDPMFKSA-N 0.000 description 1
- CCPZFLPAWVBBRN-HNKHHVNMSA-N CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)[C@@H]1[C@@H](C1)C#N Chemical compound CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)[C@@H]1[C@@H](C1)C#N CCPZFLPAWVBBRN-HNKHHVNMSA-N 0.000 description 1
- CCPZFLPAWVBBRN-DMRZNYOFSA-N CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)[C@H]1[C@H](C1)C#N Chemical compound CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)[C@H]1[C@H](C1)C#N CCPZFLPAWVBBRN-DMRZNYOFSA-N 0.000 description 1
- HMDCZVBGULZIIM-CALCHBBNSA-N CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C1(CN(C1)S(=O)(=O)C)CC#N Chemical compound CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C1(CN(C1)S(=O)(=O)C)CC#N HMDCZVBGULZIIM-CALCHBBNSA-N 0.000 description 1
- JSOOKLFPJNXYMJ-IYBDPMFKSA-N CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C1(COC1)CC#N Chemical compound CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C1(COC1)CC#N JSOOKLFPJNXYMJ-IYBDPMFKSA-N 0.000 description 1
- GTXCSFLZRFJUBT-CALCHBBNSA-N CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C1=NC=CC(=C1)C#N Chemical compound CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C1=NC=CC(=C1)C#N GTXCSFLZRFJUBT-CALCHBBNSA-N 0.000 description 1
- PSERGXHXHPELAD-JOHJCKIYSA-N CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C1CC(C1)C#N Chemical compound CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C1CC(C1)C#N PSERGXHXHPELAD-JOHJCKIYSA-N 0.000 description 1
- XJSBQOKCJDKSQL-OKILXGFUSA-N CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C=1OC(=CN=1)C#N Chemical compound CN1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C=1OC(=CN=1)C#N XJSBQOKCJDKSQL-OKILXGFUSA-N 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 102000003858 Chymases Human genes 0.000 description 1
- 108090000227 Chymases Proteins 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- GYSKAZTUAKFQGF-GASCZTMLSA-N ClC=1C(=NC=C(C=1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)C1CC1)C(=O)NC Chemical compound ClC=1C(=NC=C(C=1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)C1CC1)C(=O)NC GYSKAZTUAKFQGF-GASCZTMLSA-N 0.000 description 1
- NATIWSKQHJEQLR-OKILXGFUSA-N ClC=1C=C(C=NC=1C(NC)=O)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)NCC Chemical compound ClC=1C=C(C=NC=1C(NC)=O)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)NCC NATIWSKQHJEQLR-OKILXGFUSA-N 0.000 description 1
- WGHSWYHCROPHPI-ZNMIVQPWSA-N ClC=1C=C(C=NC=1CCO)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)[C@H]1C(C1)(F)F Chemical compound ClC=1C=C(C=NC=1CCO)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)[C@H]1C(C1)(F)F WGHSWYHCROPHPI-ZNMIVQPWSA-N 0.000 description 1
- FSMINCWIXBWFEQ-ZNMIVQPWSA-N ClC=1C=C(C=NC=1OCCO)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)[C@H]1C(C1)(F)F Chemical compound ClC=1C=C(C=NC=1OCCO)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(=O)[C@H]1C(C1)(F)F FSMINCWIXBWFEQ-ZNMIVQPWSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 102000003837 Epithelial Sodium Channels Human genes 0.000 description 1
- 108090000140 Epithelial Sodium Channels Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- UDIPGJHIDQGUMQ-UHFFFAOYSA-N FC(C(=O)N1C2CN(CC1C2)C1=NC(=NC=C1F)NC1=CC(=C(C(=O)NCC)C=C1)C)(C)F Chemical compound FC(C(=O)N1C2CN(CC1C2)C1=NC(=NC=C1F)NC1=CC(=C(C(=O)NCC)C=C1)C)(C)F UDIPGJHIDQGUMQ-UHFFFAOYSA-N 0.000 description 1
- CBQRXVIZYPISHJ-QXMXGUDHSA-N FC1(C(C1)CN1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NNC=1)F Chemical compound FC1(C(C1)CN1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NNC=1)F CBQRXVIZYPISHJ-QXMXGUDHSA-N 0.000 description 1
- OSZZEVLKVTVTLV-GASCZTMLSA-N FC1(CC(C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F Chemical compound FC1(CC(C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F OSZZEVLKVTVTLV-GASCZTMLSA-N 0.000 description 1
- WUBDSQXZQWXQOO-OKILXGFUSA-N FC1(CC1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C Chemical compound FC1(CC1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C WUBDSQXZQWXQOO-OKILXGFUSA-N 0.000 description 1
- VIXNYZLRQAAYHS-XHSDSOJGSA-N FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC1=CC(=NC(=C1)C)C(=O)NC)F Chemical compound FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC1=CC(=NC(=C1)C)C(=O)NC)F VIXNYZLRQAAYHS-XHSDSOJGSA-N 0.000 description 1
- DDSWYIFIOLPNTC-XHSDSOJGSA-N FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC1=CC(=NC(=C1)CO)C(=O)NC)F Chemical compound FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC1=CC(=NC(=C1)CO)C(=O)NC)F DDSWYIFIOLPNTC-XHSDSOJGSA-N 0.000 description 1
- SMDARHPYQAFXMU-BBWFWOEESA-N FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=CC(=NC=1)C(C#N)(C)C)F Chemical compound FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=CC(=NC=1)C(C#N)(C)C)F SMDARHPYQAFXMU-BBWFWOEESA-N 0.000 description 1
- BMASSXKNVQHFPK-ZNMIVQPWSA-N FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NC(=C(C=1)F)CCO)F Chemical compound FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NC(=C(C=1)F)CCO)F BMASSXKNVQHFPK-ZNMIVQPWSA-N 0.000 description 1
- WNTYMRBAVODLGO-LZWOXQAQSA-N FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NC(=C(C=1)F)N1CC(C1)O)F Chemical compound FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NC(=C(C=1)F)N1CC(C1)O)F WNTYMRBAVODLGO-LZWOXQAQSA-N 0.000 description 1
- KOSULRGUNRLXHZ-TWMKSMIVSA-N FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NC(=C(C=1)F)N1C[C@@H](CC1)O)F Chemical compound FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NC(=C(C=1)F)N1C[C@@H](CC1)O)F KOSULRGUNRLXHZ-TWMKSMIVSA-N 0.000 description 1
- KOSULRGUNRLXHZ-YVSFHVDLSA-N FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NC(=C(C=1)F)N1C[C@H](CC1)O)F Chemical compound FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NC(=C(C=1)F)N1C[C@H](CC1)O)F KOSULRGUNRLXHZ-YVSFHVDLSA-N 0.000 description 1
- LRZYHCZKTOWDMP-BHYGNILZSA-N FC1([C@@H](C1)CN1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=C(C(=NC=1)C(=O)NC)C)F Chemical compound FC1([C@@H](C1)CN1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=C(C(=NC=1)C(=O)NC)C)F LRZYHCZKTOWDMP-BHYGNILZSA-N 0.000 description 1
- BQSFRXRHBCYARB-AEGPPILISA-N FC1([C@@H](C1)CN1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F Chemical compound FC1([C@@H](C1)CN1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F BQSFRXRHBCYARB-AEGPPILISA-N 0.000 description 1
- LRZYHCZKTOWDMP-OIISXLGYSA-N FC1([C@H](C1)CN1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=C(C(=NC=1)C(=O)NC)C)F Chemical compound FC1([C@H](C1)CN1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=C(C(=NC=1)C(=O)NC)C)F LRZYHCZKTOWDMP-OIISXLGYSA-N 0.000 description 1
- BQSFRXRHBCYARB-YUELXQCFSA-N FC1([C@H](C1)CN1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F Chemical compound FC1([C@H](C1)CN1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F BQSFRXRHBCYARB-YUELXQCFSA-N 0.000 description 1
- KIHZWVVXKDIMBF-YYIAUSFCSA-N F[C@H]1[C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=C(C(=NC=1)C(=O)NC)C Chemical compound F[C@H]1[C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=C(C(=NC=1)C(=O)NC)C KIHZWVVXKDIMBF-YYIAUSFCSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000003458 I kappa b kinase inhibitor Substances 0.000 description 1
- 229940127590 IRAK4 inhibitor Drugs 0.000 description 1
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010018976 Interleukin-8A Receptors Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- XWQKSEWBFRDMOR-LQDVMPOASA-N N1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(CC#N)C Chemical compound N1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2C(CC#N)C XWQKSEWBFRDMOR-LQDVMPOASA-N 0.000 description 1
- CWFZISZFDCTJJR-GASCZTMLSA-N N1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2CC1(CC1)C#N Chemical compound N1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2CC1(CC1)C#N CWFZISZFDCTJJR-GASCZTMLSA-N 0.000 description 1
- WPJBRIKPIROPTE-OKILXGFUSA-N N1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2CCC#N Chemical compound N1N=CC(=C1)NC1=NC=CC(=N1)N1C[C@H]2CC[C@@H](C1)N2CCC#N WPJBRIKPIROPTE-OKILXGFUSA-N 0.000 description 1
- FTWXOPFWALRIRF-UHFFFAOYSA-N N=1N=CCC=1S(=O)(=O)N Chemical compound N=1N=CCC=1S(=O)(=O)N FTWXOPFWALRIRF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- FVIKTAZVQBLBAI-BETUJISGSA-N O1N=CC=C1C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NNC=1 Chemical compound O1N=CC=C1C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NNC=1 FVIKTAZVQBLBAI-BETUJISGSA-N 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 102100028045 P2Y purinoceptor 2 Human genes 0.000 description 1
- 101710096700 P2Y purinoceptor 2 Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 1
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 description 1
- 102000048176 Prostaglandin-D synthases Human genes 0.000 description 1
- 108030003866 Prostaglandin-D synthases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 102000000551 Syk Kinase Human genes 0.000 description 1
- 108010016672 Syk Kinase Proteins 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- 102100028644 Tenascin-R Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000533 adrenergic alpha-1 receptor agonist Substances 0.000 description 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000002163 alpha 1-adrenoceptor agonist Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000000040 apocrine gland Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 108010041776 cardiotrophin 1 Proteins 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
- 239000002573 chemokine receptor CXCR2 antagonist Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229950001653 cilomilast Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000010250 cytokine signaling pathway Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 108700032141 ganirelix Proteins 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000035929 gnawing Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 229960002491 ibudilast Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- BEHYAANJUKYBTH-UHFFFAOYSA-N imidazo[1,2-a]pyridine-2-carboxamide Chemical compound C1=CC=CC2=NC(C(=O)N)=CN21 BEHYAANJUKYBTH-UHFFFAOYSA-N 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 208000005005 intertrigo Diseases 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- OTZRAYGBFWZKMX-JUDRUQEKSA-N leukotriene E4 Chemical compound CCCCCC=CCC=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O OTZRAYGBFWZKMX-JUDRUQEKSA-N 0.000 description 1
- 108010052322 limitin Proteins 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229940127212 long-acting beta 2 agonist Drugs 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960005192 methoxamine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229960002259 nedocromil sodium Drugs 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012740 non-selective inhibitor Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- DWJMBQYORXLGAE-UHFFFAOYSA-N pyridine-2-sulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=N1 DWJMBQYORXLGAE-UHFFFAOYSA-N 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 102000000568 rho-Associated Kinases Human genes 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 229950008160 tanezumab Drugs 0.000 description 1
- 108010020387 tenascin R Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Abstract
利用抑制包括Janus激酶(JAK)在内的某些激酶的化合物及类似物来治疗化脓性汗腺炎的方法。
Description
技术领域
本发明提供利用抑制包括Janus激酶(JAK)在内的某些激酶的化合物及类似物来治疗化脓性汗腺炎的方法。
背景技术
蛋白激酶是催化蛋白中特定残基的磷酸化的酶家族,大体分为酪氨酸激酶和丝氨酸/苏氨酸激酶。由突变、过度表达或不适当的调节、异常调节或去调节以及生长因子或细胞因子的过度生产或生产不足引起的不适当的激酶活性与许多疾病有牵连,包括但不限于癌症、心血管疾病、过敏、哮喘和其他呼吸道疾病、自身免疫性疾病、炎症性疾病、骨疾病、代谢病症和神经性病症及神经退行性病症,例如阿尔兹海默病。不适当的激酶活性会触发与前面提及的疾病以及相关的疾病牵连的涉及细胞生长、细胞分化、细胞功能、存活、凋亡和细胞迁移的多种生物细胞反应。
因此,蛋白激酶已作为用于治疗干预的靶标的一类重要的酶出现。特别地,细胞蛋白酪氨酸激酶(JAK1、JAK2、JAK3和Tyk2)的JAK家族在细胞因子信号传导中起重要作用(Kisseleva等人, Gene, 2002, 285, 1; Yamaoka等人Genome Biology 2004, 5, 253)。细胞因子一结合至它们的受体就会激活JAK,然后JAK将细胞因子受体磷酸化,从而为信号传导分子,特别是最终导致基因表达的信号转导与转录激活因子(signal transducer andactivator of transcription, STAT)家族的成员生成对接位点(docking site)。已知许多细胞因子激活JAK家族。这些细胞因子包括:干扰素(IFN)家族(IFN-α、IFN-β、IFN-Ω、限制素(Limitin)、IFN-γ、IL-10、IL-19、IL-20、IL-22)、gp130家族(IL-6、IL-11、OSM、LIF、CNTF、NNT-1/BSF-3、G-CSF、CT-1、瘦素(Leptin)、IL-12、IL-23),γC家族(IL-2、IL-7、TSLP、IL-9、IL-15、IL-21、IL-4、IL-13)、IL-3家族(IL-3、IL-5、GM-CSF)、单链家族(EPO、GH、PRL、TPO)、受体酪氨酸激酶(EGF、PDGF、CSF-1、HGF)和G蛋白偶联受体(AT1)。
化脓性汗腺炎(HS)是一种慢性、炎症性、复发性、使人衰弱的皮肤疾病,通常出现在***之后,在机体的顶泌腺承载区域伴有疼痛、深层、发炎的病变。Zouboulis, C.等人, Dermatology, 231(2), 第184-190页(2015)。HS呈现出可变的临床过程。该疾病的主要特征之一是擦烂的发生,虽然皮肤的其他区域也可能受到影响。受影响的区域按频率降低的顺序为:腹股沟、腋窝、***和肛周以及女性的乳腺下的褶皱和/或***间的褶皱、臀部、***、头皮、耳后区域和眼睑。
在西欧,自我报告疾病的患病率约为1%。从症状起始到诊断的平均间隔为7.2年。女性受影响的频率是男性的2-5倍,并且该疾病在黑人中可能比在白人中更普遍。疾病的严重程度范围从轻度(局部的病变)到重度(多个区域的广泛分散的病变,包括相互连接的窦道和增生性瘢痕)。瘢痕形成引起的疼痛、引流和运动范围限制可降低生活质量。Jemec,G.B., New Eng. J. Med., 366: 158-64 (2012); Kimball, A.等人, New Eng. J. Med., 375(5), 第422-434页(2016)。
疼痛是HS的一个突出特征,其以最近定义的核心结局指标集反映,该核心结局指标集将在未来的试验中进行评估。Thorlacius, L.等人, Brit. J. Derm., 179(3), 第642-650页(2018)。大多数患者用数字评价量表-11(NRS 11)评价他们的疼痛的范围是4/10-10/10,并且在不同时间将其描述为热、烧灼、压力拉伸、切割、尖锐、绷紧、***、啃咬、压痛、抽痛和疼痛。目前,阿达木单抗是唯一获批的用于中度至重度HS的医学治疗。这是基于阿达木单抗用于HS的两个类似设计的(PIONEER I和PIONEER II ) 3期多中心试验。Kimball, A.等人, New Eng. J. Med., 375(5), 第422-434页(2016)。PIONEER I共招募307名患者,且PIONEER II共招募326名患者。每周接受阿达木单抗的组在第12周的临床响应率[化脓性汗腺炎临床响应(HiSCR)]:定义为脓肿和炎症性结节计数较基线减少至少50%,且脓肿或引流瘘管计数未增加]显著高于安慰剂组:在PIONEER I中为41.8%对26.0%(P= 0.003)且在PIONEER II中为58.9%对27.6%(P<0.001)。仅在PIONEER II中接受阿达木单抗的患者在第12周的等级排序次要结局(病变、疼痛和疾病严重程度的改良Sartorius评分)的改善显著大于安慰剂组。Kimball, A.等人, 同上。研究设计之间的主要区别为:在PIONEER I中要求接受用于HS的口服抗生素药剂的患者在基线之前停止治疗至少28天;在PIONEER II中,允许患者继续以稳定的剂量用抗生素(四环素类)治疗。
因此,相当数量的中度至重度HS患者(约40%)对阿达木单抗的治疗无响应,并且由此仍然存在对中度至重度HS患者的有效、安全并且耐受性良好的治疗的未满足的需求。本文公开了抑制某些激酶(例如JAK1、Tyk2/JAK1和Tyk2)的化合物和类似物对治疗HS有用的发现。相应地,本文描述了减少人受试者中HS症状的严重程度的方法。这些方法可以包括对受试者给予包含有效减少炎症性病变(例如,结节、脓肿或引流瘘管)的数量和/或尺寸、阻止其进展、减少由其引起的疼痛或延迟进一步的病变发展的这类化合物的药物组合物的步骤。
发明内容
本发明提供用于治疗受试者的化脓性汗腺炎的方法,所述方法包含对有需要的受试者给予本文所公开的抑制JAK (例如JAK1、Tyk2/JAK1和Tyk2)的任何化合物。
在一些实施方案中,本发明提供用于治疗受试者的化脓性汗腺炎的方法,所述方法包含对有需要的受试者给予N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}丙烷-1-磺酰胺或其药用盐。
在另一方面,本发明提供用于治疗受试者的化脓性汗腺炎的方法,所述方法包含以0.01mg/kg体重/天至约100mg/kg体重/天的剂量对有需要的受试者给予N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}丙烷-1-磺酰胺。
在一些实施方案中,本发明提供用于治疗受试者的化脓性汗腺炎的方法,所述方法包含对有需要的受试者给予[(1S)-2,2-二氟环丙基][(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环-[3.2.1]辛-8-基]甲酮或其药用盐。
在另一方面,本发明提供用于治疗受试者的化脓性汗腺炎的方法,所述方法包含以0.01mg/kg体重/天至约100mg/kg体重/天的剂量对有需要的受试者给予[(1S)-2,2-二氟环丙基][(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环-[3.2.1]辛-8-基]甲酮。
在一些实施方案中,本发明提供用于治疗受试者的化脓性汗腺炎的方法,所述方法包含对有需要的受试者给予(1r, 3r)-3-(氰基甲基)-3-(4-(6-(1-甲基-1H-吡唑-4-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)环丁烷-1-甲腈或其药用盐。
在另一方面,本发明提供用于治疗受试者的化脓性汗腺炎的方法,所述方法包含以0.01mg/kg体重/天至约100mg/kg体重/天的剂量对有需要的受试者给予(1r, 3r)-3-(氰基甲基)-3-(4-(6-(1-甲基-1H-吡唑-4-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)环丁烷-1-甲腈。
根据本发明的治疗的临床效益可以通过例如化脓性汗腺炎临床响应评分(HiSCR)来测量。
在一些实施方案中,JAK抑制剂有效改善HiSCR评分。
如本文所述,还提供JAK抑制剂在制造用于在治疗和预防受试者的化脓性汗腺炎的方法中使用的药物中的用途。
从以下仅以示例的方式给出的描述将进一步理解本发明。虽然本发明不受此限制,但是通过以下讨论和实施例将获得对本发明的不同方面的领会。
如本文所使用的,“受试者”是指哺乳动物、伴侣动物或家畜动物。
术语“伴侣动物(companion animal)”或“伴侣动物(companion animals)”是指作为宠物或家庭动物饲养的动物。伴侣动物的示例包括狗、猫和包括仓鼠、豚鼠、沙鼠等的啮齿动物、兔、雪貂和鸟类。
术语“家畜”是指为制作产品(例如食物或纤维),或者为其劳力而养育或抚养在农业设置中的动物。在一些实施方案中,家畜适合被哺乳动物例如人食用。家畜动物的示例包括牛、山羊、马、猪、绵羊(包括小羊)和兔以及鸟类(例如鸡、鸭和火鸡)。
术语“治疗(treating)”或“治疗(treatment)”意为减轻与疾病、病症或状况相关的症状,或停止这些症状的进一步进展或恶化。取决于患者的疾病和状况,如本文所使用的术语“治疗”可以包括治愈、姑息及预防性治疗中的一种或多种。治疗也可以包括将本发明的药物制剂与其他的疗法联合给药。
术语“治疗有效的”表明药剂预防病症或改善其严重程度,同时避免通常与替代疗法相关的不利的副作用的能力。词组“治疗有效的”应理解为等价于词组“对于治疗、预防或改进是有效的”,并且两者都旨在限定用于联合疗法中使用的每种药剂的量,所述联合疗法将实现每种药剂单独治疗期间疾病或其疼痛或其他症状的严重程度以及发病频率的改善目标,同时避免通常与替代疗法相关的不利的副作用。
“药学上可接受的”意为适合用于“受试者”。
具体实施方式
本发明涉及用于治疗受试者的化脓性汗腺炎的方法,该方法包含对有需要的受试者给予抑制某些JAK(例如JAK1、Tyk2/JAK1和Tyk2)的化合物。本发明进一步提供包含这类抑制剂的药物组合物。相应地,本发明提供用于治疗具有与化脓性汗腺炎相关的病变的受试者的化脓性汗腺炎的方法,该方法包含对有需要的受试者给予选自以下的化合物的步骤:
[(1S)-2,2-二氟环丙基]{(1R,5S)-3-[2-({5-氟-6-[(3S)-3-羟基吡咯烷-1-基]吡啶-3-基}氨基)嘧啶-4-基]-3,8-二氮杂二环[3.2.1]辛-8-基}甲酮;
(1R,5S)-N-乙基-3-[2-(1,2-噻唑-4-基氨基)嘧啶-4-基]-3,8-二氮杂二环[3.2.1]辛烷-8-甲酰胺;
4-{(1R,5S)-8-[(2,2-二氟环丙基)甲基]-3,8-二氮杂二环[3.2.1]辛-3-基}-N-(1H-吡唑-4-基)嘧啶-2-胺;
(1R,5S)-3-(2-{[5-氯-6-(甲基氨甲酰基)吡啶-3-基]氨基}嘧啶-4-基)-N-乙基-3,8-二氮杂二环[3.2.1]辛烷-8-甲酰胺;
环丙基[(1R,5S)-3-(2-{[1-(2-羟基乙基)-1H-吡唑-4-基]氨基}嘧啶-4-基)-3,8-二氮杂二环[3.2.1]辛-8-基]甲酮;
N-(1-甲基-1H-吡唑-4-基)-4-{(1R,5S)-8-[1-(甲基磺酰基)氮杂环丁烷-3-基]-3,8-二氮杂二环[3.2.1]辛-3-基}嘧啶-2-胺;
4-({4-[(1R,5S)-8-{[(1S)-2,2-二氟环丙基]羰基}-3,8-二氮杂二环[3.2.1]辛-3-基]嘧啶-2-基}氨基)-N,6-二甲基吡啶-2-甲酰胺;
5-({4-[(1R,5S)-8-{[(1R,2S)-2-氟环丙基]羰基}-3,8-二氮杂二环[3.2.1]辛-3-基]嘧啶-2-基}氨基)-N,3-二甲基嘧啶-2-甲酰胺;
环丙基[(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]甲酮;
3-{(1R,5S)-3-[2-(1H-吡唑-4-基氨基)嘧啶-4-基]-3,8-二氮杂二环[3.2.1]辛-8-基}丁腈;
5-({4-[(1R,5S)-8-(环丙基羰基)-3,8-二氮杂二环[3.2.1]辛-3-基]嘧啶-2-基}氨基)-N-乙基-3-甲基吡啶-2-甲酰胺;
3-[(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]丁腈;
5-({4-[(1R,5S)-8-(环丙基羰基)-3,8-二氮杂二环[3.2.1]辛-3-基]嘧啶-2-基}氨基)-3-甲基吡啶-2-甲酰胺;
(1R,5S)-N-乙基-3-(2-{[5-氟-6-(甲基氨甲酰基)吡啶-3-基]氨基}嘧啶-4-基)-3,8-二氮杂二环[3.2.1]辛烷-8-甲酰胺;
3-氯-5-({4-[(1R,5S)-8-(环丙基羰基)-3,8-二氮杂二环[3.2.1]辛-3-基]嘧啶-2-基}氨基)-N-甲基吡啶-2-甲酰胺;
(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-N-(丙-2-基)-3,8-二氮杂二环[3.2.1]辛烷-8-甲酰胺;
(3,3-二氟环丁基)[(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]甲酮;
1-({(1R,5S)-3-[2-(1H-吡唑-4-基氨基)嘧啶-4-基]-3,8-二氮杂二环[3.2.1]辛-8-基}甲基)环丙烷甲腈;
3-[(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]丁腈;
(1S,2R)-2-{[(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]羰基}环丙烷甲腈;
(1R,2S)-2-{[(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]羰基}环丙烷甲腈;
[(1R,2R)-2-氟环丙基][(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]甲酮;
[(1R,2R)-2-氟环丙基][(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]甲酮;
(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛烷-8-甲酰胺;
(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-N-[5-(三氟甲基)吡啶-2-基]-3,8-二氮杂二环[3.2.1]辛烷-8-甲酰胺;
N,3-二甲基-5-[(4-{(1R,5S)-8-[(3-甲基氧杂环丁烷-3-基)甲基]-3,8-二氮杂二环[3.2.1]辛-3-基}嘧啶-2-基)氨基]吡啶-2-甲酰胺;
{3-[(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]-1-(甲基磺酰基)氮杂环丁烷-3-基}乙腈;
4-({4-[8-(氰基乙酰基)-3,8-二氮杂二环[3.2.1]辛-3-基]嘧啶-2-基}氨基)-N-乙基苯甲酰胺;
(1R,5S)-N-(氰基甲基)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛烷-8-甲酰胺;
5-({4-[(1R,5S)-8-{[(1S,2R)-2-氟环丙基]羰基}-3,8-二氮杂二环[3.2.1]辛-3-基]嘧啶-2-基}氨基)-N,3-二甲基吡啶-2-甲酰胺;
5-({4-[(1R,5S)-8-(顺式-3-氰基环丁基)-3,8-二氮杂二环[3.2.1]辛-3-基]嘧啶-2-基}氨基)-N,3-二甲基吡啶-2-甲酰胺;
5-({4-[(1R,5S)-8-{[(1R)-2,2-二氟环丙基]甲基}-3,8-二氮杂二环[3.2.1]辛-3-基]嘧啶-2-基}氨基)-N,3-二甲基吡啶-2-甲酰胺;
N,3-二甲基-5-({4-[(1R,5S)-8-(1,2-噁唑-5-基甲基)-3,8-二氮杂二环[3.2.1]辛-3-基]嘧啶-2-基}氨基)吡啶-2-甲酰胺;
2-[5-({4-[(1R,5S)-8-{[(1S)-2,2-二氟环丙基]羰基}-3,8-二氮杂二环[3.2.1]辛-3-基]嘧啶-2-基}氨基)吡啶-2-基]-2-甲基丙腈;
3-{(1R,5S)-3-[2-(1H-吡唑-4-基氨基)嘧啶-4-基]-3,8-二氮杂二环[3.2.1]辛-8-基}丙腈;
(1R,5S)-N-乙基-3-[2-(1H-吡唑-4-基氨基)嘧啶-4-基]-3,8-二氮杂二环[3.2.1]辛烷-8-甲酰胺;
4-[(1R,5S)-8-{[(1S)-2,2-二氟环丙基]甲基}-3,8-二氮杂二环[3.2.1]辛-3-基]-N-(1-甲基-1H-吡唑-4-基)嘧啶-2-胺;
[(1S)-2,2-二氟环丙基][(1R,5S)-3-(2-{[5-氟-6-(2-羟基乙基)吡啶-3-基]氨基}嘧啶-4-基)-3,8-二氮杂二环[3.2.1]辛-8-基]甲酮;
[(1S)-2,2-二氟环丙基][(1R,5S)-3-(2-{[5-氟-6-(3-羟基氮杂环丁烷-1-基)吡啶-3-基]氨基}嘧啶-4-基)-3,8-二氮杂二环[3.2.1]辛-8-基]甲酮;
[(1R,5S)-3-(2-{[5-氯-6-(2-羟基乙氧基)吡啶-3-基]氨基}嘧啶-4-基)-3,8-二氮杂二环[3.2.1]辛-8-基][(1S)-2,2-二氟环丙基]甲酮;
{3-[(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]氧杂环丁烷-3-基}乙腈;
[(1R,5S)-3-(2-{[5-氯-6-(2-羟基乙基)吡啶-3-基]氨基}嘧啶-4-基)-3,8-二氮杂二环[3.2.1]辛-8-基][(1S)-2,2-二氟环丙基]甲酮;
2-[(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]吡啶-4-甲腈;
3-[(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]环丁烷甲腈;
2-[(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]-1,3-噁唑-5-甲腈;
(1R,5S)-N-(2-氰基乙基)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛烷-8-甲酰胺;
N-(1-甲基-1H-吡唑-4-基)-4-[(1R,5S)-8-(1,2-噁唑-4-基甲基)-3,8-二氮杂二环[3.2.1]辛-3-基]嘧啶-2-胺;
4-({4-[(1R,5S)-8-{[(1S)-2,2-二氟环丙基]羰基}-3,8-二氮杂二环[3.2.1]辛-3-基]嘧啶-2-基}氨基)-6-(羟基甲基)-N-甲基吡啶-2-甲酰胺;
(1-氟环丙基)[(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]甲酮;
N-(1-甲基-1H-吡唑-4-基)-4-[(1R,5S)-8-(1,3-噻唑-2-基甲基)-3,8-二氮杂二环[3.2.1]辛-3-基]嘧啶-2-胺;
环丙基{(1R,5S)-3-[2-(1,2-噻唑-4-基氨基)嘧啶-4-基]-3,8-二氮杂二环[3.2.1]辛-8-基}甲酮;
[(1S)-2,2-二氟环丙基]{(1R,5S)-3-[2-({5-氟-6-[(3R)-3-羟基吡咯烷-1-基]吡啶-3-基}氨基)嘧啶-4-基]-3,8-二氮杂二环[3.2.1]辛-8-基}甲酮;
5-({4-[(1R,5S)-8-{[(1S)-2,2-二氟环丙基]甲基}-3,8-二氮杂二环[3.2.1]辛-3-基]嘧啶-2-基}氨基)-N,3-二甲基吡啶-2-甲酰胺;
4-[(1R,5S)-8-{[(1R)-2,2-二氟环丙基]甲基}-3,8-二氮杂二环[3.2.1]辛-3-基]-N-(1-甲基-1H-吡唑-4-基)嘧啶-2-胺;
6-({4-[(1R,5S)-8-(环丙基羰基)-3,8-二氮杂二环[3.2.1]辛-3-基]-5-氟嘧啶-2-基}氨基)咪唑并[1,2-a]吡啶-2-甲酰胺;
5-({4-[(1R,5S)-8-(环丙基羰基)-3,8-二氮杂二环[3.2.1]辛-3-基]-5-氟嘧啶-2-基}氨基)吡啶-2-磺酰胺;
5-({4-[(1R,5S)-8-(反式-3-氰基环丁基)-3,8-二氮杂二环[3.2.1]辛-3-基]嘧啶-2-基}氨基)-N,3-二甲基吡啶-2-甲酰胺;
1,2-噁唑-5-基{(1R,5S)-3-[2-(1H-吡唑-4-基氨基)嘧啶-4-基]-3,8-二氮杂二环[3.2.1]辛-8-基}甲酮;
N-(1-甲基-1H-吡唑-4-基)-4-[(1R,5S)-8-(甲基磺酰基)-3,8-二氮杂二环[3.2.1]辛-3-基]嘧啶-2-胺;
(1S,2S)-2-{[(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]甲基}环丙烷甲腈;
3-({4-[(1R,5S)-8-(环丙基羰基)-3,8-二氮杂二环[3.2.1]辛-3-基]-5-氟嘧啶-2-基}氨基)-N-丙基-1H-吡唑-5-甲酰胺;
(1S,2S)-2-{[(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]甲基}环丙烷甲腈;
环丙基{(1R,5S)-3-[5-氟-2-(哒嗪-4-基氨基)嘧啶-4-基]-3,8-二氮杂二环[3.2.1]辛-8-基}甲酮;
4-({4-[6-(2,2-二氟丙酰基)-3,6-二氮杂二环[3.1.1]庚-3-基]-5-氟嘧啶-2-基}氨基)-N-乙基-2-甲基苯甲酰胺;
(1S,2S)-2-氰基-N-[(1S,5R,6R)-3-(2-{[6-(2-羟基乙氧基)吡啶-3-基]氨基}-5-甲基嘧啶-4-基)-6-甲基-3-氮杂二环[3.1.0]己-1-基]环丙烷甲酰胺;
N-[(1S,5R)-3-(5-氯-2-{[1-(2-羟基乙基)-1H-吡唑-4-基]氨基}嘧啶-4-基)-3-氮杂二环[3.1.0]己-1-基]环丙烷甲酰胺;
(1S)-2,2-二氟-N-[(1S,5R,6R)-3-(5-氟-2-{[1-(氧杂环丁烷-3-基)-1H-吡唑-4-基]氨基}嘧啶-4-基)-6-甲基-3-氮杂二环[3.1.0]己-1-基]环丙烷甲酰胺;
(1S)-2,2-二氟-N-[(1S,5S)-3-{5-氟-2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-5-(羟基甲基)-3-氮杂二环[3.1.0]己-1-基]环丙烷甲酰胺;
N-{(1S,5R,6R)-3-[5-氟-2-({6-[(2S)-1-羟基丙-2-基]吡啶-3-基}氨基)嘧啶-4-基]-6-甲基-3-氮杂二环[3.1.0]己-1-基}环丙烷甲酰胺;
5-[(4-{(1S,5R,6R)-1-[(环丙基羰基)氨基]-6-甲基-3-氮杂二环[3.1.0]己-3-基}-5-氟嘧啶-2-基)氨基]-N,3-二甲基吡啶-2-甲酰胺;
N-{(1S,5R,6R)-3-[2-({5-氯-6-[(1R)-1-羟基乙基]吡啶-3-基}氨基)-5-氟嘧啶-4-基]-6-甲基-3-氮杂二环[3.1.0]己-1-基}环丙烷甲酰胺;
(1R)-2,2-二氟-N-[(1R,5S,6S)-3-{5-氟-2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-6-甲基-3-氮杂二环[3.1.0]己-1-基]环丙烷甲酰胺;
5-[(4-{(1R,5S,6S)-1-[(环丙基羰基)氨基]-6-甲基-3-氮杂二环[3.1.0]己-3-基}-5-氟嘧啶-2-基)氨基]-N,3-二甲基吡啶-2-甲酰胺;
N-[(1R,5S)-3-(5-氯-2-{[1-(2-羟基乙基)-1H-吡唑-4-基]氨基}嘧啶-4-基)-3-氮杂二环[3.1.0]己-1-基]环丙烷甲酰胺;
N-{(1S,5R,6R)-3-[5-氟-2-({6-[(2R)-1-羟基丙-2-基]吡啶-3-基}氨基)嘧啶-4-基]-6-甲基-3-氮杂二环[3.1.0]己-1-基}环丙烷甲酰胺;
和(1S)-2,2-二氟-N-[(1R,5S,6S)-3-{5-氟-2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-6-甲基-3-氮杂二环[3.1.0]己-1-基]环丙烷甲酰胺;
或其药学上可接受的盐。
本发明还提供所述方法,其中所述化合物为[(1S)-2,2-二氟环丙基][(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]甲酮或其药学上可接受的盐。本发明进一步提供其中所述盐为对甲苯磺酸盐的方法。
本发明还提供所述方法,其中所述化合物为[(1R)-2,2-二氟环丙基][(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]甲酮或其药学上可接受的盐。
本发明进一步提供用于治疗具有与化脓性汗腺炎相关的病变的受试者的化脓性汗腺炎的方法,该方法包含对有需要的受试者给予选自以下的化合物的步骤:
4-氰基-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}吡啶-2-磺酰胺;
2,2,2-三氟-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}乙烷磺酰胺;
2-甲基-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}丙烷-1-磺酰胺;
N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}丙烷-1-磺酰胺;
1-环丙基-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}甲烷磺酰胺;
N-{顺式-3-[(丁基磺酰基)甲基]环丁基}-N-甲基-7H-吡咯并[2,3-d]嘧啶-4-胺;
1-环丙基N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}氮杂环丁烷-3-磺酰胺;
3-氰基-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}氮杂环丁烷-1-磺酰胺;
(1R,5S)-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}-6-氧杂-3-氮杂二环[3.1.1]庚烷-3-磺酰胺;
(3R)-3-氰基-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}吡咯烷-1-磺酰胺;
(3S)-3-氰基-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}吡咯烷-1-磺酰胺;
N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}-1-(氧杂环丁烷-3-基)甲烷磺酰胺;
1-(3,3-二氟环丁基)-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}甲烷磺酰胺;
反式-3-(氰基甲基)-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}环丁烷磺酰胺;
顺式-3-(氰基甲基)-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}环丁烷磺酰胺;
N-[顺式-3-({[(3,3-二氟环丁基)甲基]磺酰基}甲基)环丁基]-N-甲基-7H-吡咯并[2,3-d]嘧啶-4-胺;
(1S,5S)-1-氰基-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}-3-氮杂二环[3.1.0]己烷-3-磺酰胺;
(1R,5R)-1-氰基-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}-3-氮杂二环[3.1.0]己烷-3-磺酰胺;
(3R)-1-[({顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}甲基)磺酰基]吡咯烷-3-甲腈;
1-[({顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}甲基)磺酰基]-4-(三氟甲基)哌啶-4-醇;
N-(顺式-3-{[(4,4-二氟哌啶-1-基)磺酰基]甲基}环丁基)-N-甲基-7H-吡咯并[2,3-d]嘧啶-4-胺;
(3S)-1-[({顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}甲基)磺酰基]吡咯烷-3-甲腈;
N-(顺式-3-{[(3-氯-4-氟苯基)磺酰基]甲基}环丁基)-N-甲基-7H-吡咯并[2,3-d]嘧啶-4-胺;
N-(顺式-3-{[(2-环丙基乙基)磺酰基]甲基}环丁基)-N-甲基-7H-吡咯并[2,3-d]嘧啶-4-胺;
N-甲基-N-[顺式-3-({[1-(丙-2-基)吡咯烷-3-基]磺酰基}甲基)环丁基]-7H-吡咯并[2,3-d]嘧啶-4-胺;
3,3-二氟-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}环丁烷磺酰胺;
1-[3-(氰基甲基)氧杂环丁烷-3-基]-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}甲烷磺酰胺;
顺式-3-(氰基甲基)-3-甲基-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}环丁烷磺酰胺;
反式-3-(氰基甲基)-3-甲基-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}环丁烷磺酰胺;
N-(2-氰基乙基)-N-甲基-N'-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}硫酰胺;
N-{(1S,3R)-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环戊基}丙烷-1-磺酰胺;
3-(2-羟基丙-2-基)-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}苯磺酰胺;
N-(环丙基甲基)-N'-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}硫酰胺;
N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}-4-(1H-吡唑-3-基)哌啶-1-磺酰胺;
2-甲基-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}-2,6-二氢吡咯并[3,4-c]吡唑-5(4H)-磺酰胺;
N-环丙基-1-{反式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}甲烷磺酰胺;
2-[({顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}甲基)磺酰基]吡啶-4-甲腈;
(1S,3S)-3-[({顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}甲基)磺酰基]环戊烷甲腈;
(1R,3R)-3-[({顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}甲基)磺酰基]环戊烷甲腈;
1-环丙基-N-{反式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}甲烷磺酰胺;
3-氰基-N-{反式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}吡咯烷-1-磺酰胺;
N-甲基-N-{反式-3-[(丙基磺酰基)甲基]环丁基}-7H-吡咯并[2,3-d]嘧啶-4-胺;和,
2-甲基-N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}-1,3-噻唑-5-磺酰胺;
或其药学上可接受的盐。
本发明还提供所述方法,其中化合物为N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}丙烷-1-磺酰胺或其药学上可接受的盐。
本发明进一步提供用于治疗具有与化脓性汗腺炎相关的病变的受试者的化脓性汗腺炎的方法,该方法包含对有需要的受试者给予选自以下的化合物的步骤:
(1r,3r)-3-(4-(6-(3-氨基-1-甲基-1H-吡唑-4-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)-3-(氰基甲基)环丁烷-1-甲腈;
2,2'-(3-(4-(6-(1-甲基-1H-吡唑-4-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)氮杂环丁烷-1,3-二基)二乙腈;
2-((1s,3r)-1-(4-(6-(5-(羟基甲基)-1H-吡唑-3-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)-3-甲氧基环丁基)乙腈;
5-(4-(1-((1s,3r)-1-(氰基甲基)-3-甲氧基环丁基)-1H-吡唑-4-基)吡唑并[1,5-a]吡嗪-6-基)-1H-吡唑-3-甲酰胺;
(1s,3s)-3-(氰基甲基)-3-(4-(6-(5-(羟基甲基)异噁唑-3-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)环丁烷-1-甲腈;
(1r,3r)-3-(氰基甲基)-3-(4-(6-(1-甲基-1H-吡唑-4-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)环丁烷-1-甲腈;
(1s,3s)-3-(氰基甲基)-3-(4-(6-(1-甲基-1H-吡唑-4-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)环丁烷-1-甲腈;
(1r,3r)-3-(氰基甲基)-3-(4-(3-甲基-6-(1-甲基-1H-吡唑-4-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)环丁烷-1-甲腈;
2-((1r,3s)-1-(4-(6-(3-氨基-1H-吡唑-5-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)-3-甲氧基环丁基)乙腈;
2-(1-乙基-3-(4-(6-(5-(羟基甲基)-1H-吡唑-3-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)氮杂环丁烷-3-基)乙腈;
(1r,3r)-3-(氰基甲基)-3-(4-(6-(1-甲基-3-氧代-2,3-二氢-1H-吡唑-4-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)环丁烷-1-甲腈(反式异构体);
(1r,3r)-3-(氰基甲基)-3-(4-(6-(1-(羟基甲基)-1H-吡唑-4-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)环丁烷-1-甲腈;和,
或其药学上可接受的盐。
本发明还提供所述方法,其中化合物为(1r,3r)-3-(氰基甲基)-3-(4-(6-(1-甲基-1H-吡唑-4-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)环丁烷-1-甲腈或其药学上可接受的盐。
本发明还提供所述方法,其中化合物为(1s,3s)-3-(氰基甲基)-3-(4-(6-(1-甲基-1H-吡唑-4-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)环丁烷-1-甲腈或其药学上可接受的盐。
本发明还提供所述方法,其中受试者的HiSCR评分在给予化合物后得到改善。
本发明还提供所述方法,其中受试者的化脓性汗腺炎病变的中位数尺寸在给予药物组合物后减小。
本发明还提供所述方法,其中与受试者的化脓性汗腺炎病变相关的受试者的疼痛在给予化合物后减少。
本发明还提供所述方法,其中受试者发展新的化脓性汗腺炎病变的时间在给予化合物后增加。
本发明进一步提供包含以上所列的任何化合物或其药学上可接受的盐,以及药学上可接受的载体的药物组合物或兽用组合物,其用于化脓性汗腺炎的治疗和预防。
本发明还提供用于治疗具有与化脓性汗腺炎相关的病变的受试者的化脓性汗腺炎的方法,该方法包含以有效治疗受试者的化脓性汗腺炎症状的量对有需要的受试者给予抑制JAK1、Tyk2/JAK1或Tyk2的化合物的步骤。
本发明还提供方法,其中所述有效量为约0.01 mg/kg体重/天至约100 mg/kg体重/天,或更优选约0.1 mg/kg至约10.0 mg/kg,呈单剂量或作为分剂量每天给药两次、三次或四次。
本发明还提供用于治疗具有与化脓性汗腺炎相关的病变的受试者的化脓性汗腺炎的方法,该方法包含以有效治疗受试者的化脓性汗腺炎症状的量对有需要的受试者给予N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}丙烷-1-磺酰胺或其药学上可接受的盐的步骤。
本发明还提供方法,其中所述有效量为约0.01 mg/kg体重/天至约100 mg/kg体重/天,或更优选约0.1 mg/kg至约10.0 mg/kg,呈单剂量或作为分剂量每天给药两次、三次或四次。
本发明还提供用于治疗具有与化脓性汗腺炎相关的病变的受试者的化脓性汗腺炎的方法,该方法包含以有效治疗受试者的化脓性汗腺炎症状的量对有需要的受试者给予[(1S)-2,2-二氟环丙基][(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]甲酮或其药学上可接受的盐的步骤。
本发明还提供方法,其中所述有效量为约0.01 mg/kg体重/天至约100 mg/kg体重/天,或更优选约0.1 mg/kg至约10.0 mg/kg,呈单剂量或作为分剂量每天给药两次、三次或四次。本发明还提供方法,其中所述有效量为约45 mg QD给药。
本发明还提供方法,其中盐为对甲苯磺酸盐。
本发明还提供用于治疗具有与化脓性汗腺炎相关的病变的受试者的化脓性汗腺炎的方法,该方法包含以有效治疗受试者的化脓性汗腺炎症状的量对有需要的受试者给予(1r,3r)-3-(氰基甲基)-3-(4-(6-(1-甲基-1H-吡唑-4-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)环丁烷-1-甲腈或其药学上可接受的盐的步骤。
本发明还提供方法,其中所述有效量为约0.01 mg/kg体重/天至约100 mg/kg体重/天,或更优选约0.1 mg/kg至约10.0 mg/kg,呈单剂量或作为分剂量每天给药两次、三次或四次。本发明还提供方法,其中所述有效量为约400 mg QD给药。
在用于治疗哺乳动物的病症的治疗用途中,本发明的化合物或其药物组合物可以口服、肠胃外、局部、直肠、经粘膜或肠道给药。肠胃外给药包括间接注射以产生全身作用或直接注射至受折磨区域。局部给药包括治疗通过局部施加易接近的皮肤或器官,例如,眼或耳。其还包括透皮递送以产生全身作用。直肠给药包括栓剂的形式。优选给药途径为口服给药、局部给药和肠胃外给药。
本发明的药物组合物可以通过本领域熟知的方法制造,例如,通过常规的混合、溶解、制粒、糖衣丸制作、磨细、乳化、包封、冻干工艺或喷雾干燥。
根据本发明使用的药物组合物可以使用一种或多种包含赋形剂和助剂在内的药学上可接受的载体以常规方式配制,该载体促进活性化合物加工成可以药学上使用的制剂。适当的制剂取决于所选择的给药途径。药学上可接受的赋形剂和载体通常是本领域技术人员已知的,并且因此包括在本发明中。例如在Remington’s Pharmaceutical Sciences, Mack Pub. Co., New Jersey (1991)中描述了这类赋形剂和载体。本发明的制剂可设计为短效、快速释放、长效和持续释放。因此,药物制剂也可以配制为控制释放或配制为缓慢释放。
适合于本发明使用的药物组合物包括其中包含足以实现预期目的(即,控制或治疗HS)的量的活性成分的组合物。更具体地,治疗有效量意为有效预防、缓和或改进疾病的症状/体征或延长被治疗的受试者的存活的化合物的量。
在药物组合物及其单位剂型中,作为本发明的化合物的活性组分的量可以取决于给药方式、特定化合物的效力和期望的浓度而广泛变化或调整。治疗有效量的确定完全在本领域技术人员的能力内。通常,活性组分的量的范围将在组合物重量的0.01%至99%之间。
通常,活性组分用量的治疗有效量将在约0.01 mg/kg体重/天至约100 mg/kg体重/天的范围内,优选约0.1 mg/kg体重/天至10 mg/kg体重/天,更优选约0.3 mg/kg体重/天至3 mg/kg体重/天,甚至更优选约0.3 mg/kg体重/天至1.5 mg/kg体重/天。应该理解,用量可以取决于每个受试者的需求及所治疗的病症或疾病的严重程度而变化。
期望的剂量可以方便地呈现为单剂量或作为分剂量以合适的间隔(例如,每天两次、三次或更多次的亚剂量)给药。亚剂量本身可以进一步分为,例如,许多离散的、间隔松散的给药;例如从吹入器多次吸入或通过将多滴滴剂施加到眼睛中。
此外,应该理解,给药的初始用量可以增加至超过以上的较高水平以快速达到期望的血浆浓度。另一方面,初始用量可以小于最佳用量并且在治疗过程期间,可以取决于特定情况逐渐增加每日用量。如果期望,也可以将每日剂量分为多个剂量以用于给药,例如,每天两次至四次。
用于与本文所列的化合物或其药学上可接受的盐、或所述化合物或盐的药学上可接受的溶剂化物在联合疗法中使用的,尤其是在疾病的治疗中使用的适合的药剂包括:5-脂氧合酶激活蛋白(FLAP)拮抗剂;白三烯拮抗剂(LTRA)例如LTB4、LTC4、LTD4、LTE4、CysLT1或CysLT2的拮抗剂,例如孟鲁司特或扎鲁司特;组胺受体拮抗剂,例如组胺1型受体拮抗剂或组胺2型受体拮抗剂,例如氯雷他定(loratidine)、非索非那定、地氯雷他定(desloratidine)、左西替利嗪、噻吡二胺或西替利嗪;α1-肾上腺受体激动剂或α2-肾上腺受体激动剂,例如苯肾上腺素、甲氧胺、羟甲唑啉或甲基去甲肾上腺素(methylnorephrine);毒蕈碱M3受体拮抗剂,例如噻托溴铵或异丙托铵;双重毒蕈碱M3受体拮抗剂(antagononist)/β2激动剂;PDE抑制剂,例如PDE3抑制剂、PDE4抑制剂或PDE5抑制剂,例如茶碱、西地那非、伐地那非、他达拉非、异丁司特、西洛司特或罗氟司特;色甘酸钠或奈多罗米钠;环氧合酶(COX)抑制剂,例如非选择性抑制剂(例如,阿司匹林或布洛芬)或选择性抑制剂(例如塞来昔布或伐地考昔);糖皮质类固醇,例如氟替卡松、莫米松、***、***龙、布***、环索奈德或倍氯米松(beclamethasone);抗炎单克隆抗体,例如英夫利昔单抗、阿达木单抗、他尼珠单抗(tanezumab)、雷珠单抗、贝伐单抗或美泊利单抗;β2激动剂,例如沙美特罗、沙丁胺醇(albuterol)、沙丁胺醇(salbutamol)、非诺特罗或福莫特罗,尤其是长效β2激动剂;整合素(intigrin)拮抗剂,例如那他珠单抗;黏附分子抑制剂,例如VLA-4拮抗剂;激肽B1或B2受体拮抗剂;免疫抑制剂,例如IgE通路抑制剂(例如,奥马珠单抗)或环孢霉素;基质金属蛋白酶(MMP)抑制剂,例如MMP-9或MMP-12的抑制剂;速激肽NK1、NK2或NK3受体拮抗剂;蛋白酶抑制剂,例如弹性蛋白酶、胃促胰酶或组织蛋白酶(catheopsin) G的抑制剂;腺苷A2a受体激动剂;腺苷A2b受体拮抗剂;尿激酶抑制剂;多巴胺受体激动剂(例如,罗匹尼罗),尤其是多巴胺D2受体激动剂(例如,溴麦角环肽);NFκB通路调节剂,例如IKK抑制剂;细胞因子信号传导通路的进一步的调节剂,例如syk激酶、p38激酶、SPHK-1激酶、Rho激酶、EGF-R或MK-2的抑制剂;黏液溶解药剂、黏液动力学药剂或镇咳药剂;抗生素;抗病毒药剂;疫苗;趋化因子;上皮钠通道(ENaC)阻断剂或上皮钠通道(ENaC)抑制剂;核苷酸受体激动剂,例如P2Y2激动剂;血栓素抑制剂;尼克酸;5-脂氧合酶(5-LO)抑制剂,例如齐留通;黏附因子,例如VLAM、ICAM或ELAM;CRTH2受体(DP2)拮抗剂;***素D2受体(DP1)拮抗剂;造血***素D2合成酶(HPGDS)抑制剂;干扰素-β;可溶人TNF受体,例如依那西普;HDAC抑制剂;磷脂酰肌醇(phosphoinositotide)3-激酶γ (PI3Kγ)抑制剂;磷脂酰肌醇3-激酶δ (PI3Kδ)抑制剂;CXCR-1或CXCR-2受体拮抗剂;IRAK-4抑制剂;和,TLR-4或TLR-9抑制剂,包括具体提及化合物的药学上可接受的盐和所述具体提及化合物和盐的药学上可接受的溶剂化物。
化学合成
本发明的化合物可以通过本领域已知的任何方法制备。特别地,本发明的化合物可以通过流程制备,该流程通过参考在其中公开了它们的现有技术参考文献来描述。
对于特异性抑制JAK1的那些化合物,包括N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}丙烷-1-磺酰胺,制备方法公开于美国专利9,035,074号,其内容全部并入本文。
对于特异性抑制Tyk2/JAK1的那些化合物,包括[(1S)-2,2-二氟环丙基][(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]甲酮,制备方法公开于美国专利9,663,526号,其内容全部并入本文。
对于特异性抑制Tyk2的那些化合物,包括(1r,3r)-3-(氰基甲基)-3-(4-(6-(1-甲基-1H-吡唑-4-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)环丁烷-1-甲腈,制备方法公开于美国专利10,144,738号,其内容全部并入本文。
实施例
展示以下非限制性的实施例仅用于说明本发明。技术人员将理解,存在许多未例示但仍然构成本教导的一部分的等价物和变体。
实施例1
化脓性汗腺炎临床响应(HiSCR)
正在进行这项研究以提供正在检验的治疗药剂在中度至重度HS的口服治疗中的关于效力、安全性、耐受性和药物代谢动力学的数据。该研究的最大持续时间将为大约26周。这包括长达6周的筛选期、16周的给药期和4周的随访期。该研究将招募总共约192名参与者(预期提供约156名完成者)。在筛选期之后,在基线访问时符合资格标准的参与者将随机分配以接受6种治疗中的1种。将调查每种治疗药剂的一个口服剂量水平:[(1S)-2,2-二氟环丙基][(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]甲酮(45 mg QD)及(1r,3r)-3-(氰基甲基)-3-(4-(6-(1-甲基-1H-吡唑-4-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)环丁烷-1-甲腈(400 mg QD)或以3:1的比例匹配安慰剂。为了分析,组合安慰剂组以产生每个IP和安慰剂的最后IP:安慰剂比例为1:1:1:1。不超过30%的所招募的参与者将是不充分的抗TNF响应者。将根据其是否为不充分的抗TNF响应者对参与者进行分层。
相应地,不超过20%的所招募的参与者可能以伴随口服抗生素疗法以治疗HS的背景进入研究;给药方案(剂量和频率)在基线(第1天)访问之前必须已经稳定至少8周(56天),并且整个参与研究期间必须保持稳定。不认为在"按需"(PRN)基础上服用的抗生素是稳定的剂量。将根据其是否有伴随抗生素疗法的背景而对参与者进行分层。每种配置(asset)的慢性毒理学包装支持所计划的16周研究治疗持续时间。化脓性汗腺炎临床响应即所使用的主要终点被定义为:相对于基线,总脓肿和炎症性结节(AN)减少至少50%,并且脓肿计数未增加且引流瘘管计数未增加。
实施例2
病变计数
炎症性和非炎症性结节、脓肿、引流和非引流瘘管及增生性瘢痕的数量,以及物理位置(右/左腋窝、右/左***下、***间、右/左臀部、右/左腹股沟股褶皱、肛周、***、其他)将根据本领域的标准进行评估。
实施例3
脓肿计数
脓肿(变动的、有或没有引流、触痛的或疼痛的)的数量将在每个如上所定义的部位进行计数。
实施例4
炎症性结节计数
炎症性结节(触痛的、红斑的、生脓性肉芽肿病变)的数量将在每个如上所定义的部位进行计数。
实施例5
瘘管计数
瘘管(窦道,与皮肤表面相通,引流脓性液体)的数量将在每个如上所定义的部位进行计数。
实施例6
赫尔利分级(Hurley Staging)
赫尔利分级定义如下:
I级:脓肿形成,单个或多个,没有窦道和结瘢(瘢痕形成)。
II级:一个或多个分得很开的复发性脓肿,伴有道形成和结瘢(瘢痕)。
III级:跨越整个区域的多个相互连接的道和脓肿,伴有弥散性或近弥散性受累。
赫尔利分级将根据本领域的标准执行。
实施例7
改良Sartorius量表
改良Sartorius评分将通过计数以下12个解剖学部位中的病变来计算:左腋窝、右腋窝、左乳腺下/***下的区域、右乳腺下/***下的区域、***间的区域、左臀部、右臀部、左腹股沟股褶皱、右腹股沟股褶皱、肛周区域、***区域、其他。对于每个解剖学部位,计算部位的Sartorius评分如下:
涉及的解剖学部位:每个涉及的部位3分(即,在这个解剖学部位有任何病变计数>0;否则0分)。
病变(脓肿、结节、瘘管、瘢痕)的数量和评分:每个结节(炎症性和非炎症性) 2分,每个脓肿4分,每个瘘管(引流和非引流) 4分,每个增生性瘢痕1分,每个"其他"1分。
2个相关的病变之间的最长距离(即,如果没有活动性病变为0;如果2个相关病变之间的最长距离或尺寸<50 mm为2;如果2个相关病变之间的最长距离或尺寸≥50 mm且<100 mm为4;如果2个相关病变之间的最长距离或尺寸≥100 mm为6。
在每个部位中病变被正常的皮肤清楚地分开:如果所有病变都被正常外观的皮肤清楚地分开,0分;否则6分。
总的改良Sartorius评分为所有12个部位的评分的总和。
实施例8
红斑评估
对于受HS影响的每个解剖学区域,将使用范围在0 (无红色),1 (微弱但是看得清的粉红色着色),2 (中度红色着色)或3 (非常红或鲜红色着色)之间的四点顺序量表评估红斑总体程度。
Claims (15)
1.用于治疗具有与化脓性汗腺炎相关的病变的受试者的化脓性汗腺炎的方法,所述方法包含对有需要的受试者给予选自JAK1、Tyk2/JAK1和Tyk2的JAK抑制剂的步骤。
2.根据权利要求1所述的方法,其中所述Tyk2/JAK1抑制剂为[(1S)-2,2-二氟环丙基][(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]甲酮或其药学上可接受的盐。
3.根据权利要求1所述的方法,其中所述Tyk2/JAK1抑制剂为[(1R)-2,2-二氟环丙基][(1R,5S)-3-{2-[(1-甲基-1H-吡唑-4-基)氨基]嘧啶-4-基}-3,8-二氮杂二环[3.2.1]辛-8-基]甲酮或其药学上可接受的盐。
4.根据权利要求3所述的方法,其中所述盐为对甲苯磺酸盐。
5.根据权利要求1所述的方法,其中所述JAK1抑制剂为N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}丙烷-1-磺酰胺或其药学上可接受的盐。
6.根据权利要求1所述的方法,其中所述Tyk2抑制剂为(1r,3r)-3-(氰基甲基)-3-(4-(6-(1-甲基-1H-吡唑-4-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)环丁烷-1-甲腈或其药学上可接受的盐。
7.根据权利要求1所述的方法,其中所述Tyk2抑制剂为(1s,3s)-3-(氰基甲基)-3-(4-(6-(1-甲基-1H-吡唑-4-基)吡唑并[1,5-a]吡嗪-4-基)-1H-吡唑-1-基)环丁烷-1-甲腈或其药学上可接受的盐。
8.根据权利要求1-7所述的方法,其中治疗减少如通过受试者的HiSCR评分所测量的炎症性结节、脓肿和引流瘘管。
9.根据权利要求1-7所述的方法,其中治疗减小受试者的化脓性汗腺炎病变的中位数尺寸。
10.根据权利要求1-7所述的方法,其中治疗减少与受试者的化脓性汗腺炎病变相关的受害者的疼痛。
11.根据权利要求1-7所述的方法,其中治疗增加受试者发展新的化脓性汗腺炎病变的时间。
12.用于治疗具有与化脓性汗腺炎相关的病变的人受试者的化脓性汗腺炎的方法,所述方法包含以有效治疗受试者的化脓性汗腺炎症状的量对有需要的受试者给予选自JAK1,Tyk2/JAK1或Tyk2的JAK抑制剂的步骤。
13. 根据权利要求12所述的方法,其中所述有效量为约0.01 mg/kg体重/天至约100mg/kg体重/天,呈单剂量或作为分剂量每天给药两次、三次或四次。
14.用于治疗具有与化脓性汗腺炎相关的病变的人受试者的化脓性汗腺炎的方法,所述方法包含以有效治疗受试者的化脓性汗腺炎症状的量对有需要的受试者给予N-{顺式-3-[甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基]环丁基}丙烷-1-磺酰胺或其药学上可接受的盐。
15. 根据权利要求14所述的方法,其中所述有效量为约0.01 mg/kg体重/天至约100mg/kg体重/天,呈单剂量或作为分剂量每天给药两次、三次或四次。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962899133P | 2019-09-11 | 2019-09-11 | |
US62/899133 | 2019-09-11 | ||
PCT/IB2020/058333 WO2021048736A1 (en) | 2019-09-11 | 2020-09-08 | Treatment of hidradenitis with jak inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114667148A true CN114667148A (zh) | 2022-06-24 |
Family
ID=72473596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080078318.5A Pending CN114667148A (zh) | 2019-09-11 | 2020-09-08 | 用jak抑制剂治疗汗腺炎 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP4028007A1 (zh) |
JP (1) | JP2021042204A (zh) |
KR (1) | KR20220059519A (zh) |
CN (1) | CN114667148A (zh) |
AR (1) | AR119942A1 (zh) |
AU (1) | AU2020347561A1 (zh) |
BR (1) | BR112022004221A2 (zh) |
CA (1) | CA3153676A1 (zh) |
IL (1) | IL291146A (zh) |
MX (1) | MX2022002995A (zh) |
TW (1) | TW202123940A (zh) |
WO (1) | WO2021048736A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230293544A1 (en) * | 2022-03-17 | 2023-09-21 | Pfizer Inc. | Methods, dosage regimens, and compositions for treating hidradenitis |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105008362A (zh) * | 2013-02-22 | 2015-10-28 | 辉瑞大药厂 | 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3-d]嘧啶衍生物 |
CN107074867A (zh) * | 2014-08-21 | 2017-08-18 | 辉瑞公司 | 作为jak抑制剂的氨基嘧啶基化合物 |
WO2018071794A1 (en) * | 2016-10-14 | 2018-04-19 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
CN109071546A (zh) * | 2016-02-24 | 2018-12-21 | 辉瑞大药厂 | 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017143014A1 (en) * | 2016-02-16 | 2017-08-24 | Brian Kim | Jak inhibitors and uses thereof |
IL302865A (en) * | 2018-03-30 | 2023-07-01 | Incyte Corp | Use of JAK inhibitors to treat hidradenitis suppurativa |
WO2019191679A1 (en) * | 2018-03-30 | 2019-10-03 | Incyte Corporation | Biomarkers for inflammatory skin disease |
-
2020
- 2020-09-08 MX MX2022002995A patent/MX2022002995A/es unknown
- 2020-09-08 KR KR1020227011306A patent/KR20220059519A/ko unknown
- 2020-09-08 AU AU2020347561A patent/AU2020347561A1/en active Pending
- 2020-09-08 CA CA3153676A patent/CA3153676A1/en active Pending
- 2020-09-08 BR BR112022004221A patent/BR112022004221A2/pt unknown
- 2020-09-08 WO PCT/IB2020/058333 patent/WO2021048736A1/en active Application Filing
- 2020-09-08 EP EP20771628.3A patent/EP4028007A1/en active Pending
- 2020-09-08 CN CN202080078318.5A patent/CN114667148A/zh active Pending
- 2020-09-10 TW TW109131138A patent/TW202123940A/zh unknown
- 2020-09-10 JP JP2020151758A patent/JP2021042204A/ja active Pending
- 2020-09-11 AR ARP200102525A patent/AR119942A1/es unknown
-
2022
- 2022-03-06 IL IL291146A patent/IL291146A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105008362A (zh) * | 2013-02-22 | 2015-10-28 | 辉瑞大药厂 | 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3-d]嘧啶衍生物 |
CN107074867A (zh) * | 2014-08-21 | 2017-08-18 | 辉瑞公司 | 作为jak抑制剂的氨基嘧啶基化合物 |
CN109071546A (zh) * | 2016-02-24 | 2018-12-21 | 辉瑞大药厂 | 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物 |
WO2018071794A1 (en) * | 2016-10-14 | 2018-04-19 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
Non-Patent Citations (1)
Title |
---|
SHI YU DEREK LIM等: "Systematic review of immunomodulatory therapies for hidradenitis suppurativa", BIOLOGICS: TARGETS AND THERAPY, vol. 13, 1 May 2019 (2019-05-01), pages 3 * |
Also Published As
Publication number | Publication date |
---|---|
TW202123940A (zh) | 2021-07-01 |
WO2021048736A1 (en) | 2021-03-18 |
AR119942A1 (es) | 2022-01-19 |
EP4028007A1 (en) | 2022-07-20 |
KR20220059519A (ko) | 2022-05-10 |
JP2021042204A (ja) | 2021-03-18 |
BR112022004221A2 (pt) | 2022-05-31 |
AU2020347561A1 (en) | 2022-04-14 |
IL291146A (en) | 2022-05-01 |
MX2022002995A (es) | 2022-06-02 |
CA3153676A1 (en) | 2021-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190388410A1 (en) | Combinations of inhibitors of irak4 with inhibitors of btk | |
JP2020050682A (ja) | ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤 | |
US10064866B2 (en) | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors | |
JP2022184886A (ja) | Alk阻害剤およびshp2阻害剤を含む組合せ医薬 | |
EP2554544A1 (en) | Pyridin-2(1h)-one derivatives as jak inhibitors | |
AU2013234767B2 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds | |
JP2016529285A (ja) | 細胞増殖性疾患を治療するためのalk阻害剤とcdk阻害剤との組合せ | |
EP4000624A1 (en) | Btk inhibitors for treating splenomegaly | |
US20220054472A1 (en) | Methods of Treating Myeloproliferative Neoplasms | |
TW202308610A (zh) | 用於治療結節性癢疹之jak1途徑抑制劑 | |
US20230149407A1 (en) | Methods of Treating Coronavirus Disease 2019 | |
CN114667148A (zh) | 用jak抑制剂治疗汗腺炎 | |
RU2805595C1 (ru) | Лечение гидраденита ингибиторами jak | |
JP2023506118A (ja) | 皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用 | |
KR20210013168A (ko) | 건선성 관절염의 치료 방법 | |
US20210113566A1 (en) | Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp) | |
US20230293544A1 (en) | Methods, dosage regimens, and compositions for treating hidradenitis | |
US11642343B2 (en) | Methods of treating splenomegaly | |
US20240058343A1 (en) | Treatment of urticaria using jak inhibitors | |
RU2786570C2 (ru) | Комбинированная терапия тетрациклическими аналогами хинолона для лечения рака | |
TW202329976A (zh) | P13K—δ抑制劑之局部調配物 | |
WO2023203022A1 (en) | Treatment of neutrophilic dermatoses | |
EA042956B1 (ru) | Ингибиторы пути jak1, предназначенные для лечения связанных с цитокинами нарушений | |
Price et al. | Momelotinib hydrochloride. JAK1/JAK2 inhibitor, Treatment of myelofibrosis, Treatment of pancreatic cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40071871 Country of ref document: HK |